Compare Ascendis Pharma A/S (ASND) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Five9 Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Five9 Inc trades at $25.5 (market cap $1.95B). The key difference: Ascendis Pharma A/S is far larger — about 9.1× Five9 Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Five9 Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FIVN | |
|---|---|---|
Market Cap | $17.74B | $1.95B |
Sector | Health | Technology |
52-Week High | $277.18 | $29.16 |
52-Week Low | $163.32 | $13.61 |
Enterprise Value | $18.11B | $2.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Five9 (FIVN) trades at $25.42, up 1.97% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $779M in 2022 to $1.15B in 2025 and a shift to profitability. Recent Q1 2026 earnings beat expectations, and the stock benefits from strong analyst support (61% buy rating) and a $27 consensus price target. However, negative net cash flow and ongoing legal scrutiny present near-term headwinds.
The outlook remains positive given consistent earnings beats and strategic leadership appointments, but risks include insider selling and litigation concerns. Upside potential exists if the company maintains its growth trajectory and addresses cash flow challenges, making it a watch for growth-oriented investors despite volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
